Patents by Inventor Gary J. Jesmok

Gary J. Jesmok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    Patent number: 6969515
    Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus. The method is applicable to the dissolution of thrombi in artificial devices, e.g., hemodialysis grafts.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: November 29, 2005
    Assignee: Talecris Biotherapeutics, Inc.
    Inventors: Gary J. Jesmok, Kyle A. Landskroner
  • Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    Patent number: 6964764
    Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: November 15, 2005
    Assignee: Talecris Biotherapeutics, Inc.
    Inventors: Thomas P. Zimmerman, Valery Novokhatny, Kyle A. Landskroner, Gary J. Jesmok, Kathryn K. Taylor
  • Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    Publication number: 20030175264
    Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus. The method is applicable to the dissolution of thrombi in artificial devices, e.g., hemodialysis grafts.
    Type: Application
    Filed: October 25, 2002
    Publication date: September 18, 2003
    Inventors: Gary J. Jesmok, Kyle A. Landskroner
  • Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    Publication number: 20030026798
    Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.
    Type: Application
    Filed: May 10, 2002
    Publication date: February 6, 2003
    Inventors: Thomas P. Zimmerman, Valery Novokhatny, Kyle A. Landskroner, Gary J. Jesmok, Kathryn K. Taylor
  • Method of thrombolysis by local delivery of active plasmin
    Patent number: 6355243
    Abstract: The invention provides an improved method of thrombolytic therapy by the direct admiistration of active plasmin to a clot site via catheter. An active, stable preparation of plasmin is provided, as is a process for activation and isolation of active plasmin.
    Type: Grant
    Filed: November 13, 1999
    Date of Patent: March 12, 2002
    Assignee: Bayer Corporation
    Inventors: Valery V. Novokhatny, Gary J. Jesmok, Kyle A. Landskroner, Kathryn K. Taylor, Thomas P. Zimmerman